蚂蚁集团正在持续打造"AI超级医生助理"，可整合患者病历、影像及最新医学指南，生成结构化诊断建 议并提供权威文献支持，助力医生提升诊疗效率。同时通过医疗大模型一体化实现本地化部署，保障数 据安全。去年已面向用户推出"AI健康管家"，已覆盖找医生、读报告、医保咨询等核心需求，支持健康 自测及体检报告解读，接入60多位名医AI智能体，累计服务功能近百种，半年服务超4,000万用户。 智通财经APP获悉，香港计算机学会金融科技专家小组执行委员会成员陈婉真表示，今年可谓AI应用爆 发元年，港府与学界连手推出HKGAI V1大模型。该模型基于DeepSeek架构进行全参数微调，不仅能流 畅处理粤语对话，更深度整合香港法律文书与公务流程。这种"本地化AI"路径，正成为城市治理的创新 范式──既保留技术自主性，又融入本地文化基因。 在产业方面，港府积极应对AI引领的新一轮技术革命和产业变革，包括建设AI超算中心、推出30亿港 元AI资助计划等，现时科学园及数码港亦汇聚逾800间AI相关企业。同时引进办自投运两年以来累计引 进84间重点企业，当中超过三成五属于数据科学与AI企业，蚂蚁数科亦成为其中一间重点引进企业并 将海外总 ...

Group 1 - The core viewpoint of the articles highlights the significant rise of Ark Health (方舟健客) stock, which increased by 8.23% to HKD 4.34, with a trading volume of HKD 40.77 million, following a report in Nature about China's medical AI models [1] - The Nature report emphasizes China's chronic disease management model, which integrates AI with various chronic disease management practices, showcasing a successful case that is rare globally [1] - The report indicates that while there are few large-scale companies in the overseas market that deeply integrate AI with chronic disease management, China's innovative forces are emerging in this field, potentially allowing for a leapfrog development [1] Group 2 - Ark Health's "super digital brain," the Xing Shi model, drives five major applications: AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, each tailored for specific clinical and patient scenarios [2] - Each application provides real-time and precise assistance in areas such as medication guidance, patient education, diagnostic support, and medical literature queries [2] - The AI academic assistant product enhances efficiency and user engagement by offering expert-level answers with voice interaction capabilities, catering to the busy clinical environment of doctors [2]

Core Insights - A revolution in health management driven by AI is underway, addressing the challenges posed by an aging population and a high prevalence of chronic diseases in China [1][2] - The online chronic disease management market in China is projected to grow from 45.5 billion yuan in 2023 to 600 billion yuan by 2030, with a compound annual growth rate of 44.5% [1] - Companies are increasingly integrating AI into chronic disease management, with Ark Health achieving a revenue of 1.494 billion yuan in the first half of the year, marking a 12.9% year-on-year increase and a return to profitability [1] Industry Developments - The Chinese government is promoting the use of new technologies in healthcare, aiming to enhance the capabilities and efficiency of grassroots medical services [2] - The rapid development of internet healthcare has significantly improved chronic disease management by breaking geographical barriers and enhancing patient compliance [3] - AI is reshaping the internet healthcare paradigm, with companies focusing on practical solutions to improve healthcare access and quality [4] Technological Innovations - Ark Health has launched an intelligent consultation service that has conducted nearly 400,000 consultations, reducing the average consultation time from 30 minutes to 20 minutes [5] - Companies are developing a range of AI products for healthcare, including AI medication assistants and health managers, creating a comprehensive service ecosystem [5] - The integration of AI in chronic disease management is not limited to the physician's side but also extends to patients and the industry [5] Challenges and Opportunities - Despite the promising outlook for AI in chronic disease management, challenges remain in data privacy, technology implementation, and sustainable business models [6] - The growing demand for weight management solutions in China presents an opportunity for AI applications in managing chronic diseases related to obesity [7] - Companies that understand both healthcare and AI are positioned to drive the core value of medical AI, which is to achieve healthcare accessibility [8]

Core Insights - The article emphasizes that chronic disease management in China is entering a new era driven by AI, highlighting the importance of technology in addressing healthcare challenges posed by an aging population [1][2] - The online chronic disease management market in China is projected to grow significantly, with a compound annual growth rate of 44.5%, from 45.5 billion yuan in 2023 to 600 billion yuan by 2030 [1] - Ark Health's AI-driven approach aims to create a patient-centered healthcare model, leveraging technology to enhance doctor-patient relationships and improve service efficiency [2][3] Technology Development - Ark Health's "Xing Shi Medical Model" is designed to integrate various intelligent components into a collaborative service team, aiming for state-of-the-art performance [3] - The AI assistant has reportedly saved doctors over 60,000 hours of time through its diagnostic and case analysis capabilities [3] - The company has developed five core AI products, including AI Medication Finder and AI Health Manager, which aim to enhance clinical decision-making and knowledge dissemination [4] Strategic Collaborations - Ark Health has formed strategic partnerships with pharmaceutical companies, such as Innovent Biologics, to target the rapidly growing weight management market, which is expected to reach 149 billion yuan by 2030 [6][7] - The collaboration with Innovent focuses on integrating AI technology with innovative weight loss products, providing comprehensive support for patients [6][8] - The partnership with Zhejiang Otsuka Pharmaceutical aims to enhance drug service offerings and health education through AI capabilities [7][8]

董事会亦留意到，公司就其于2025年9月10日举行的第十届H2H医疗服务生态大会而刊发的新闻稿，其 中包括若干公司最新消息，包括(i)公司发布专有「杏石」大模型("杏石大模型")作为其五项旗舰应用(AI 用药助手、AI健康管家、AI医生助手、AI学术助手及AI搜索)的基石，赋能先进临床诊断支援及个性化 慢病管理；(ii)与信达生物制药("信达")达成战略合作伙伴关系，整合方舟H2H数字健康生态系统与信达 体重管理疗法管线，初步利用公司之杏石大模型，为信达的玛仕度肽提供个性化数字维护及依从性支 持，在中国快速增长的体重管理市场提高患者的疗效；及(iii)与浙江大塚制药有限公司("大塚")展开战略 合作，结合公司的AI技术优势及大塚的创新药组合，共同开发覆盖药物支援服务、针对性病患外展项 目及健康教育计划的全方位数字解决方案。 经作出在相关情况下有关公司的该等合理查询后，董事会确认(i)新闻稿所含资料并不构成根据上市规则 第13.09(2)条或香港法例第571章证券及期货条例第XIVA部项下之内幕消息条文所规定之内幕消息；及 (ii)其亦并不知悉股份交易价格上升之任何理由，或为避免股份出现虚假市场而须作出公告之任 ...

Core Viewpoint - Ark Health (06086) has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025, following the announcement of its strategic initiatives and partnerships in the healthcare sector [1]. Group 1: Company Developments - The company has launched its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications, including AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, aimed at enhancing clinical diagnostic support and personalized chronic disease management [1]. - Ark Health has formed a strategic partnership with Innovent Biologics to integrate its H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model to provide personalized digital maintenance and adherence support for Innovent's Ma Shidu peptide in China's rapidly growing weight management market [1]. - The company has also entered into a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., combining its AI technology advantages with Otsuka's innovative drug portfolio to jointly develop comprehensive digital solutions covering drug support services, targeted patient outreach programs, and health education initiatives [1]. Group 2: Regulatory Confirmation - The board has confirmed that the information contained in the press release does not constitute inside information as defined under the Listing Rules and relevant securities regulations, and it is unaware of any reasons for the increase in share price or any information that needs to be disclosed to avoid creating a false market in its shares [2].

Group 1 - The company, Ark Health (06086), has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - A strategic partnership has been established with Innovent Biologics to integrate Ark's H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital maintenance and compliance support in China's growing weight management market [1] - The company has also formed a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., Ltd. to develop comprehensive digital solutions that combine AI technology with Otsuka's innovative drug portfolio, focusing on drug support services, targeted patient outreach programs, and health education initiatives [1] Group 2 - The board confirmed that the information contained in the press release does not constitute insider information as defined under the relevant listing rules and securities regulations [2] - The board is not aware of any reasons for the increase in share price or any information that would require disclosure to prevent a false market in the shares [2]

Core Insights - Fangzhou Jianke has achieved profitability with a revenue of 1.494 billion yuan, marking a 12.9% growth, and a net profit of 12.5 million yuan as of mid-2025 [3] - The company employs a "familiar doctor-patient" model, focusing on relationship reconstruction rather than merely chasing traffic [4][5] - The AI-powered "Xing Shi Medical Model" aims to enhance the efficiency of its H2H (Hospital to Home) healthcare ecosystem [6][9] Company Performance - Fangzhou Jianke's user base has grown to over 52.8 million registered users and 229,000 registered doctors by mid-2025, with a high repurchase rate of 84.7% among paying users [4] - The company’s growth is driven by value-based internal growth, reducing reliance on continuous traffic purchases [5] AI Integration - The "Xing Shi Medical Model" integrates a comprehensive knowledge base from the Chinese Medical Association, covering over 1.1 million articles across 170 core journals [6] - Five core AI products have been launched, creating a collaborative network across medical, patient, and enterprise sectors [7] Efficiency Improvements - The AI Doctor Assistant has saved over 60,000 hours of work for doctors by providing nearly 400,000 technical assists, allowing them to focus on more complex diagnoses [8] - The AI Health Manager has reduced average consultation times by over 70%, significantly enhancing patient experience [8] Future Vision - By 2025, the company aims to integrate AI assistants into daily medical practices, with daily usage exceeding 100,000 times [10] - The ultimate goal is to establish "Fangzhou Medical Smart Cloud" by 2027, serving as an authoritative clinical decision standard across the industry [10]

具体而言，在药事服务领域，依托AI用药助手的实时响应能力，肥胖症患者无需等待即可获得7x24小 时在线咨询、在线找药、用药问答等专业支持，彻底打破传统药事服务的时空限制。在体重管理方面， AI健康管家作为患者的全天候健康管理伙伴，能提供个性化用药指导、服务提醒与管理、报告解读与 知识科普等延伸服务，不仅提供心理上的抚慰，还降低了其决策成本，实现患者健康素养与自我管理能 力有效提升。 消息面上，9月10日，在方舟健客第十届H2H医疗服务生态大会上，国内领先的AI+慢病管理企业方舟 健客与信达生物正式签署战略合作协议。据介绍，方舟健客将依托其AI技术成果、H2H智慧医疗新生态 和数智化行业经验，重塑慢病患者全周期管理流程，构建个性化、一体式的健康管理新体验。基于本次 战略合作的良好开端，双方未来将发挥各自优势，推动创新治疗方案与AI技术驱动的数智化健康管理 深度融合，携手构建"AI+减重"领域的服务新范式。 方舟健客(06086)盘中涨超7%，截至发稿，涨6.65%，报4.65港元，成交额2854.33万港元。 ...

Core Viewpoint - Ark Health (06086) has seen a stock price increase of over 7%, currently trading at 4.65 HKD, following the announcement of a strategic partnership with Innovent Biologics to enhance chronic disease management through AI technology [1] Group 1: Strategic Partnership - Ark Health signed a strategic cooperation agreement with Innovent Biologics at the 10th H2H Medical Service Ecosystem Conference on September 10 [1] - The partnership aims to leverage Ark Health's AI technology and industry experience to reshape the full-cycle management process for chronic disease patients [1] - Both companies will work together to integrate innovative treatment solutions with AI-driven health management [1] Group 2: AI-Driven Services - The collaboration will focus on creating a new service paradigm in the "AI + Weight Loss" sector [1] - In the pharmaceutical service area, the AI medication assistant will provide 24/7 online consultation, medication inquiries, and support for obesity patients without waiting time [1] - The AI health manager will serve as a round-the-clock health management partner, offering personalized medication guidance, service reminders, and educational resources to enhance patient self-management capabilities [1]